Diabetes mellitus type combinations

Sitagliptin is a dipeptidylpeptidase-4 inhibitor that increases insulin secretion and lowers glucagon secretion. Sitagliptin is available for oral administration. It is indicated in patients with type 2 diabetes mellitus in combination with either metformin (biguanide) or a sulphonylurea or a thiazolidinedione. 

Rosiglitazone 9, an agonist of peroxisome proliferator activated receptor-y (PPARy), is a recently introduced antihyperglycemic thiazolidinedione effective in the treatment of noninsulin dependant diabetes mellitus (type II diabetes). A seven-step synthesis was developed (Scheme 3), which utilised supported reagents in combination with in-line SPE purifications. The introduction of the pyridine moiety provided a convenient molecular handle by which to purify the molecule throughout the synthesis. Notably, the overall yield (46%) for this synthesis was higher than the yield reported in the initial shorter solution-phase synthesis (31%). ... 

Generally, autoimmune diseases are perceived to be rare however, when all autoimmune diseases are combined, the estimated prevalence of 3-5% is not rare, which underlines their importance in the public health sector. Because of problems in designing and standardizing epidemiological studies and because of the fact that only limited data are available, this prevalence may be underestimated (Jacobson et al., 1997). There is epidemiological evidence of increasing prevalence of some autoimmune diseases (e.g. diabetes mellitus type 1, multiple sclerosis), although the rates for other diseases (specifically, rheumatoid arthritis, or RA) appear to be... 

The least well characterized autoimmune polyglandular syndrome is the type 3 syndrome. This syndrome is defined by the presence of autoimmune thyroid disease with another autoimmune disease, such as diabetes mellitus type l, autoimmune gastritis, or myasthenia gravis, but in the absence of Addison disease. APGS type 3 primarily involves females (the female to male ratio is 7 1) who have HLA-DR3-associated autoimmune disease and is probably the most common of the autoimmune polyglandular syndrome disorders. Since different and multiple clinical combinations can be found, the classification of this type of autoimmune polyglandular syndrome is probably more complicated than originally anticipated. 

Metabolism Prickly pear cactus is a popular food among Mexicans, Mexican-Ameri-cans, and Hispanics and is commonly used to treat type 2 diabetes mellitus. The combination of prickly pear cactus with oral hypoglycemic agents, such as metformin and glipizide, in patients with type 2 diabetes mellitus may increase the risk of hypoglycemia because of additive blood glucose lowering effects [70" ]. 

Diabetes mellitus is defined as hyperglycaemia (fasting > 7 mM and/or 2 h postprandial >11.1 mM) due to absolute or relative lack of insulin. The most common forms are type 1 diabetes (prevalence 0.25%), with absolute lack of insulin, and type 2 diabetes (prevalence 4-6%) which is due to the combination of insulin resistance and insufficient insulin secretion. 

Insulin is necessary for controlling type 1 diabetes mellitus that is caused by a marked decrease in the amount of insulin produced by die pancreas. Insulin is also used to control the more severe and complicated forms of type 2 diabetes mellitus. However, many patients can control type 2 diabetes with diet and exercise alone or with diet, exercise, and an oral antidiabetic drug (see section Oral Antidiabetic Dmgp ). Insulin may also be used in the treatment of severe diabetic ketoacidosis (DKA) or diabetic coma. Insulin is also used in combination with glucose to treat hypokalemia by producing a shift of potassium from die blood and into die cells. 

Type 2 diabetes mellitus Adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea. 

Type 2 diabetes mellitus As an adjunct to diet and exercise to lower the blood glucose in patients with type 2 diabetes mellitus and in combination with metformin or thiazolidinediones to lower blood glucose in patients whose hyperglycemia cannot be controlled by exercise, diet, and either agent alone. 

Sitagliptin is a selective dipeptidylpeptidase 4 (DPP-4) inhibitor which increases the active form of GLP-1 (glucagon-like-peptide-1) and GIP (glucose-dependent insulinotropic peptide). This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. Adverse effects were as common with sitagliptin (whether used alone or with metformin or pioglitazone) as they were with placebo, except for nausea and common cold-like symptoms. 

It is indicated in the management of type II diabetes mellitus as monotherapy or in combination. 

Millions of people with type I (insulin-dependent) diabetes mellitus inject themselves daily with pure insulin to compensate for the lack of production of this critical hormone by their own pancreatic fi cells. Insulin injection is not a cure for diabetes, but it allows people who otherwise would have died young to lead long and productive lives. The discovery of insulin, which began with an accidental observation, illustrates the combination of serendipity and careful experimentation that led to the discovery of many of the hormones. 

Kerenyi Z, Samer H, James R, Yan Y Stewart M. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004 63 213-23. 

Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus a randomized, placebo-controlled study. Am J Med 2001 lll(l) 10-7. 

Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus a randomized controlled trial. JAMA 2000 283(13) 1695-702. 

In a randomized trial in 74 patients with chronic hepatitis C treated with interferon alfa-2b and ribavirin, plus placebo or amantadine, two developed glutamic acid decarboxylase (GAD) autoantibodies, but none developed IA-2 or insulin autoantibodies (543). One had an increased titer of GAD autoantibodies during a first sequence of interferon alfa monotherapy, then a further rise during subsequent combination therapy, and finally developed diabetes mellitus after 5 months of treatment. The authors suggested that repetitive treatment with interferon alfa could increase the risk of type 1 diabetes in patients previously positive for islet antibodies. 

Type 2, also known previously as non-insulin-dependent diabetes mellitus (NIDDM), accounts for 90 to 95 percent of persons with diabetes mellitus.19 This form of diabetes usually occurs in adults, especially in older individuals.35,102 Type 2 diabetes, however, can also occur in young people, and there is concern that the incidence of this disease is increasing dramatically in children and adolescents.9,83 Although the specific factors responsible for this disease are unknown, a genetic predisposition combined with poor diet, obesity, and lack of exercise all seem to contribute to the onset of type 2 diabetes.50,81,83 Increased body weight is common in patients with type 2 diabetes. 

Finally, insulin resistance is present in disease states other than type 2 diabetes mellitus. Patients with conditions such as hypertension, obesity, and certain hyperlipidemias are also found to have decreased tissue sensitivity to circulating insulin.19,72 As discussed in Chapter 21, a combination of these abnormalities is often described as metabolic syndrome, or syndrome X.127,128 Metabolic syndrome occurs when insulin resistance, high blood pressure, abdominal... 

The islet cells of the pancreas synthesize and secrete insulin and glucagon. These hormones are important in regulating glucose uptake and use, as well as in other aspects of energy metabolism. Problems in the production and effects of insulin are typical of a disease known as diabetes mellitus. Diabetes mellitus can be categorized into two primary forms type 1 diabetes, which is caused by an absolute deficiency of insulin, and type 2 diabetes, which is caused by a decrease in peripheral insulin effects, combined with abnormal insulin release. 

Chip kin SR. How to select and combine oral agents for patients with type 2 diabetes mellitus. Am J Med. 2005 118(suppl 5A) 4S-13S. 

Metabolic disorders are common, especially diabetes mellitus, a disorder of the glucose control. Most serious is type 1 diabetes, where the beta cells are destructed, typically by an autoimmune reaction, so the patient must be given insulin the rest of his/her life. Untreated it can lead to death within some months to a few years. It attacks mainly younger adults or children. The second, called type 2 diabetes, affects older people, typically in their 60s and typically obese. The disease is a combination of a decreased insulin production and an impaired glucose disposal. It evolves slowly and many patients can, at least in the beginning, be controlled with diet and exercise. 

HMR1964 (INN insulin glulisine) is a human insulin analogue for the treatment of Type I and Type II patients with diabetes mellitus. Combinations of insulin preparations that differ both in their time of onset and duration of action are used optimally to control blood glucose in patients with diabetes mellitus. The most commonly used insulin regimens include a long-acting in-... 

---